Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Karo Pharma AB. See also section “IMPORTANT INFORMATION” below.

Karo Pharma AB (“Karo Pharma”) has prepared a prospectus supplement, in addition to the prospectus regarding the fully guaranteed rights issue announced on 11 May 2018, which has today been approved and registered by the Swedish Financial Supervisory Authority. The prospectus supplement is available on Karo Pharma’s website www.karopharma.se, on SEB’s website www.sebgroup.com/prospectuses and on Swedbank’s website www.swedbank.se/prospekt.

The Supplementary Prospectus has been prepared due to Karo Pharma’s press release on 21 May 2018 regarding the receipt of a milestone payment regarding the RORgamma project from Pfizer.

Investors who prior the publication of this Supplementary Prospectus have applied for or otherwise consented to subscribe for shares in the Offer are pursuant to Chapter 2, Section 34 of the Swedish Financial Instruments Trading Act entitled to withdraw their application or consent within two business days from the publication of the Supplementary Prospectus, i.e., until 25 May 2018. Revocation must be made in writing to Swedbank AB (publ), Emissioner C85, SE-105 34 Stockholm, Sweden, or by e-mail to emissioner@swedbank.se. Investors who have subscribed for shares through a nominee shall contact their nominee for revocation. Application that is not withdrawn within the specified time frame will remain binding and investors who do not wish to withdraw their application for subscription of shares do not have to take any action.

Financial and legal advisors

SEB Corporate Finance and Swedbank Corporate Finance are Joint Global Coordinators and Hamilton Advokatbyrå is legal advisor to Karo Pharma in relation to the rights issue.


Peter Blom, CEO, +46 (0) 70-655 56 98 or peter.blom@karopharma.se   

The information was submitted for publication, through the above contact person´s agency, at 17:30 CEST on 23 May 2018. This press release is also available at www.karopharma.se and www.newsroom.cision.com.


Karo Pharma is a Specialty Pharmaceutical company, which develops and markets products for pharmacies as well as directly to the healthcare sector. Karo Pharma is listed on Nasdaq Stockholm, Mid Cap.      


The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Karo Pharma AB. Any invitation to the persons entitled to subscribe for shares in Karo Pharma AB is made solely through the prospectus which Karo Pharma AB publishes on 11 May 2018.

This press release may not be released, published or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, Singapore, the United States or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares have or will be registered under the United States Securities Act of 1933 (“Securities Act”) or securities legislation in any state or other jurisdiction in the United States and may not be offered, subscribed, used, pledged, sold, resold, allotted, delivered or transferred, directly or indirectly, into or within the United States, other than pursuant to an exemption from, or in a transaction that is subject to, the registration requirements of the Securities Act. The offering is not aimed for individuals with residence in Australia, Hong Kong, Switzerland, and Singapore nor in any other jurisdiction where participation would require additional prospectus, registration or other arrangements aside of the Swedish law system.

Related documents

Press release (PDF)